Design Therapeutics, Inc. Earnings Per Share, Basic and Diluted
Design Therapeutics, Inc. (DSGN) reported Earnings Per Share, Basic and Diluted of -$0.24 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-09.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-09
- Design Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.24.
- Design Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.20, a 170.55% decline year-over-year.
- Design Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.21.
- Design Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.14.
- Design Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2021 was -$0.77.
- Design Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2020 was -$0.52.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$0.24 10-Q · filed 2022-05-09 | -$0.44 derived: net income ÷ weighted average shares · filed 2023-05-09 | -$0.64 derived: net income ÷ weighted average shares · filed 2023-05-09 | -$0.78 derived: net income ÷ weighted average shares · filed 2023-05-09 |
| 2021-12-31 | -$0.20 derived: net income ÷ weighted average shares · filed 2023-03-14 | -$0.40 derived: net income ÷ weighted average shares · filed 2023-03-14 | -$0.54 derived: net income ÷ weighted average shares · filed 2023-03-14 | -$0.77 10-K · filed 2022-03-10 |
| 2021-09-30 | -$0.21 10-Q · filed 2021-11-09 | -$0.34 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$0.57 10-Q · filed 2021-11-09 | -$0.99 derived: net income ÷ weighted average shares · filed 2022-11-03 |
| 2021-06-30 | -$0.14 10-Q · filed 2021-08-09 | -$0.36 10-Q · filed 2021-08-09 | -$0.86 derived: net income ÷ weighted average shares · filed 2022-08-08 | -$0.91 derived: net income ÷ weighted average shares · filed 2022-08-08 |
| 2021-03-31 | -$0.31 10-Q · filed 2022-05-09 | -$4.69 derived: net income ÷ weighted average shares · filed 2022-05-09 | -$1.18 derived: net income ÷ weighted average shares · filed 2022-05-09 | -$0.95 derived: net income ÷ weighted average shares · filed 2022-05-09 |
| 2020-12-31 | $0.28 derived: net income ÷ weighted average shares · filed 2022-03-10 | -$1.02 derived: net income ÷ weighted average shares · filed 2022-03-10 | -$0.61 derived: net income ÷ weighted average shares · filed 2022-03-10 | -$0.52 10-K · filed 2022-03-10 |
| 2020-09-30 | -$0.09 10-Q · filed 2021-11-09 | -$0.15 derived: net income ÷ weighted average shares · filed 2021-11-09 | -$0.17 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$0.06 10-Q · filed 2021-08-09 | -$0.08 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | -$0.04 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |